Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

doi:10.1056/NEJMc2200133

. 2022 Mar 31;386(13):1288-1290.

doi: 10.1056/NEJMc2200133. Epub 2022 Feb 9.

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

Heba N Altarawneh¹, Hiam Chemaitelly¹, Mohammad R Hasan², Houssein H Ayoub³, Suelen Qassim¹, Sawsan AlMukdad¹, Peter Coyle⁴, Hadi M Yassine³, Hebah A Al-Khatib³, Fatiha M Benslimane³, Zaina Al-Kanaani⁴, Einas Al-Kuwari⁴, Andrew Jeremijenko⁴, Anvar H Kaleeckal⁴, Ali N Latif⁴, Riyazuddin M Shaik⁴, Hanan F Abdul-Rahim³, Gheyath K Nasrallah³, Mohamed G Al-Kuwari⁵, Adeel A Butt⁴, Hamad E Al-Romaihi⁶, Mohamed H Al-Thani⁶, Abdullatif Al-Khal⁴, Roberto Bertollini⁶, Patrick Tang², Laith J Abu-Raddad⁷

Affiliations

¹ Weill Cornell Medicine-Qatar, Doha, Qatar.
² Sidra Medicine, Doha, Qatar.
³ Qatar University, Doha, Qatar.
⁴ Hamad Medical Corporation, Doha, Qatar.
⁵ Primary Health Care, Doha, Qatar.
⁶ Ministry of Public Health, Doha, Qatar.
⁷ Weill Cornell Medicine-Qatar, Doha, Qatar lja2002@qatar-med.cornell.edu.

PMID: 35139269
PMCID: PMC8849180
DOI: 10.1056/NEJMc2200133

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

Heba N Altarawneh et al. N Engl J Med. 2022.

. 2022 Mar 31;386(13):1288-1290.

doi: 10.1056/NEJMc2200133. Epub 2022 Feb 9.

Authors

Affiliations

¹ Weill Cornell Medicine-Qatar, Doha, Qatar.
² Sidra Medicine, Doha, Qatar.
³ Qatar University, Doha, Qatar.
⁴ Hamad Medical Corporation, Doha, Qatar.
⁵ Primary Health Care, Doha, Qatar.
⁶ Ministry of Public Health, Doha, Qatar.
⁷ Weill Cornell Medicine-Qatar, Doha, Qatar lja2002@qatar-med.cornell.edu.

PMID: 35139269
PMCID: PMC8849180
DOI: 10.1056/NEJMc2200133

No abstract available

PubMed Disclaimer

Comment in

Protection Due to Previous SARS-CoV-2 Infection.
Jolobe OMP. Jolobe OMP. N Engl J Med. 2022 Jun 23;386(25):2444. doi: 10.1056/NEJMc2205555. Epub 2022 Jun 8. N Engl J Med. 2022. PMID: 35675204 No abstract available.

Cited by

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial.
Chew CK, Wang R, Bavanandan S, Zainudin N, Zhao X, Ahmed S, Nair D, Hou L, Yahya R, Ch'ng SS, Pang LH, Abdul Aziz A, Huang H, Rajasuriar R, Wu S, Zhang Z, Wang X, Chun GY, Mohd Norzi A, Cheah KY, Lee YL, Wan Mohamad WH, Mohd Din MR, Wan Ahmad Kamil WMR, Tan MH, Xu X, Wang L, Yan M, Liu Y, Chin VK, Teo JS, Lim TO, Zhu T, Gou J, Ng SSM. Chew CK, et al. NPJ Vaccines. 2024 Oct 31;9(1):209. doi: 10.1038/s41541-024-01003-x. NPJ Vaccines. 2024. PMID: 39482336 Free PMC article.
Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions.
Pham LV, Underwood AP, Binderup A, Fahnøe U, Fernandez-Antunez C, Lopez-Mendez B, Ryberg LA, Galli A, Sølund C, Weis N, Ramirez S, Bukh J. Pham LV, et al. Emerg Microbes Infect. 2024 Dec;13(1):2412643. doi: 10.1080/22221751.2024.2412643. Epub 2024 Nov 13. Emerg Microbes Infect. 2024. PMID: 39392057 Free PMC article.
Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden.
Di Domenico L, Goldberg Y, Colizza V. Di Domenico L, et al. Infect Dis Model. 2024 Sep 12;10(1):150-162. doi: 10.1016/j.idm.2024.09.002. eCollection 2025 Mar. Infect Dis Model. 2024. PMID: 39380724 Free PMC article.
Humoral and cellular immune responses in vaccinated and unvaccinated children following SARS-CoV-2 Omicron infection.
Toh ZQ, Anderson J, Mazarakis N, Quah L, Nguyen J, Higgins RA, Do LAH, Ng YY, Jalali S, Neeland MR, McMinn A, Saffery R, McNab S, McVernon J, Marcato A, Burgner DP, Curtis N, Steer AC, Mulholland K, Pellicci DG, Crawford NW, Tosif S, Licciardi PV. Toh ZQ, et al. Clin Transl Immunology. 2024 Oct 3;13(10):e70008. doi: 10.1002/cti2.70008. eCollection 2024. Clin Transl Immunology. 2024. PMID: 39364394 Free PMC article.
Enhancing COVID-19 Vaccination Awareness and Uptake in the Post-PHEIC Era: A Narrative Review of Physician-Level and System-Level Strategies.
See KC. See KC. Vaccines (Basel). 2024 Sep 11;12(9):1038. doi: 10.3390/vaccines12091038. Vaccines (Basel). 2024. PMID: 39340068 Free PMC article. Review.

See all "Cited by" articles

References

1. Chemaitelly H, Bertollini R, Abu-Raddad LJ; National Study Group for COVID-19 Epidemiology. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N Engl J Med 2021;385:2585-2586. - PMC - PubMed
1. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study. PLoS Med 2021;18(12):e1003879-e1003879. - PMC - PubMed
1. Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of SARS-CoV-2 natural immunity and protection against the delta variant: a retrospective cohort study. Clin Infect Dis 2021. December 3 (Epub ahead of print). - PMC - PubMed
1. Ayoub HH, Tomy M, Chemaitelly H, et al. Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design. January 3, 2022. (https://www.medrxiv.org/content/10.1101/2022.01.02.22268622v1). preprint. - PMC - PubMed
1. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nat Commun 2022;13:532-532. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Chemaitelly H, Bertollini R, Abu-Raddad LJ; National Study Group for COVID-19 Epidemiology. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N Engl J Med 2021;385:2585-2586. - PMC - PubMed

[2] Chemaitelly H, Bertollini R, Abu-Raddad LJ; National Study Group for COVID-19 Epidemiology. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N Engl J Med 2021;385:2585-2586. - PMC - PubMed

[3] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study. PLoS Med 2021;18(12):e1003879-e1003879. - PMC - PubMed

[4] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study. PLoS Med 2021;18(12):e1003879-e1003879. - PMC - PubMed

[5] Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of SARS-CoV-2 natural immunity and protection against the delta variant: a retrospective cohort study. Clin Infect Dis 2021. December 3 (Epub ahead of print). - PMC - PubMed

[6] Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of SARS-CoV-2 natural immunity and protection against the delta variant: a retrospective cohort study. Clin Infect Dis 2021. December 3 (Epub ahead of print). - PMC - PubMed

[7] Ayoub HH, Tomy M, Chemaitelly H, et al. Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design. January 3, 2022. (https://www.medrxiv.org/content/10.1101/2022.01.02.22268622v1). preprint. - PMC - PubMed

[8] Ayoub HH, Tomy M, Chemaitelly H, et al. Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design. January 3, 2022. (https://www.medrxiv.org/content/10.1101/2022.01.02.22268622v1). preprint. - PMC - PubMed

[9] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nat Commun 2022;13:532-532. - PMC - PubMed

[10] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nat Commun 2022;13:532-532. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

Affiliations

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

Authors

Affiliations

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Supplementary concepts

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous